<DOC>
	<DOC>NCT00002269</DOC>
	<brief_summary>To evaluate ampligen at two dosage levels given twice weekly in combination with zidovudine (AZT) versus AZT alone in individuals with HIV-related immune dysfunction defined as T4 count between 100 and 300 cells/mm3.</brief_summary>
	<brief_title>A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>poly(I).poly(c12,U)</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<criteria>Inclusion Criteria Patients must have: HIV1 seropositivity. Absolute number of T4 cells 100300 cells/mm3. Given informed consent. Zidovudine (AZT) therapy for 6 months prior to study entry. At least one of the listed HIVrelated clinical symptoms or opportunistic infections: weight loss &gt; 10 percent, unexplained diarrhea, unexplained intermittent fever, oral candidiasis &gt; 1 month, decreased Karnofsky, oral hairy leukoplakia, chronic fatigue. Exclusion Criteria Coexisting Condition: Patients with the following conditions or symptoms are excluded: Evidence of AIDS. Intercurrent acute medical disorder. Concurrent Medication: Excluded: Chemotherapy for Kaposi's sarcoma (KS). Aspirin. Nonsteroidal antiinflammatory drugs. Patients with the following are excluded: Inability to return for treatment and evaluation for 12 months. Intercurrent acute medical disorder. Evidence of AIDS. Receiving chemotherapy for Kaposi's sarcoma (KS). Unwilling or unable to give informed consent. Required: Zidovudine (AZT). Required at least 6 months prior to study entry: Zidovudine (AZT). Active drug abuse.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1991</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>ampligen</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>